Global Scientific Director

Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ - the skin - meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin, we are in shapes our lives, we are advancing dermatology for every skin story.

We look for people who focus on getting results, embrace learning and bring a positive energy. They must combine initiative with a sense of teamwork and collaboration. Above all, they must be passionate about doing something meaningful for consumers, patients, and the healthcare professionals we serve every day. We aim to empower each employee and promote their personal growth while ensuring business needs are met now and into the future. Across our company, we embrace diversity and respect the dignity, privacy, and personal rights of every employee.

At Galderma, we actively give our teams reasons to believe in our bold ambition to become the leading dermatology company in the world. With us, you have the ultimate opportunity to gain new and challenging work experiences and create an unparalleled, direct impact.

The Global Scientific Director, Nemolizumab will play a pivotal role in shaping and executing the medical communications and publications strategy for Nemolizumab within Galderma’s dermatology portfolio.

Nemolizumab is a first in class, investigational, monoclonal antibody that directly targets the interleukin-31 receptor A, a neuroimmune cytokine. IL-31 is believed to play a role in more than 50 diseases and is a promising therapeutic target for treating multiple conditions. Nemolizumab has reported positive results of the phase 3 programs in Prurigo Nodularis and Atopic Dermatitis and is in phase 2/3 for chronic kidney disease associated pruritus. Nemolizumab is approved in the US, EU, UK, Switzerland and Australia. Nemolizumab is in phase 2/3 stage in Systemic Sclerosis (SSc) and in Chronic Pruritus of Unknown Origin (CPUO). 

The Global Scientific Director, Nemolizumab role combines strategic leadership with hands-on involvement in the development, writing, and review of high-quality scientific publications, congress abstracts, and posters. The role will oversee the Adhoc analysis plan for data that supports all publications, including aligning prioritization with business needs, and timely delivery of outputs in collaboration with the Biostats peers.

Working in close partnership with cross-functional teams—including Clinical Development, Clinical Operations, Real-World Evidence, Biostatistics, and Commercial, US Medical and US Commercial—as well as external experts and investigators, the Director will ensure scientific accuracy, alignment with brand strategy, and timely publication and communication of data to support the clinical differentiation and value proposition of Nemolizumab in dermatology.

The Director will also oversee and collaborate with external agencies and vendors to ensure the delivery of scientifically rigorous and compliant materials, while maintaining ownership of content quality and messaging consistency.

Additionally, the role includes responsibility for training cross-functional teams on newly developed and published data, ensuring broad understanding and effective application of emerging scientific insights across the organization.

Essential Functions:

The Global Scientific Director will report directly to the VP Medical Affairs USA

Primary responsibilities will include:

• Serve as the primary driver of the medical communications and publications strategy for nemolizumab within Galderma’s dermatology portfolio

• Overseeing the Adhoc analysis plan for data that supports all publications, aligning prioritization with business needs

• Lead the end-to-end creation of high-quality scientific publications, abstracts, and congress posters—personally authoring (with vendor support) and refining materials to ensure scientific rigor, clarity, and strategic alignment.

• Collaborate cross-functionally with Clinical Development, Biostatistics, Commercial, and other internal stakeholders, as well as external experts, to ensure accurate interpretation and communication of c